---
title: "HBsAg clearance and occult HBV mutation in HIV/HBV-coinfected patients on ART"
id: "medrxiv-7-hepatitis-b-surface-antigen-clearance-in-hiv-hbv-coinfected-patients-associated"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-7-hepatitis-b-surface-antigen-clearance-in-hiv-hbv-coinfected-patients-associated"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.02.26362028v1?rss=1"
published_at: "2026-09-04T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# HBsAg clearance and occult HBV mutation in HIV/HBV-coinfected patients on ART
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-7-hepatitis-b-surface-antigen-clearance-in-hiv-hbv-coinfected-patients-associated
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.02.26362028v1?rss=1)
- **Published At:** 2026-09-04T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This retrospective study reviewed 256 people with HIV followed at Kumamoto University Hospital (1986–2025) to evaluate **HBsAg clearance** and characterize occult HBV infection (OBI) in coinfected patients. 15 patients met inclusion for detailed analysis (12 HBsAg-positive, 3 OBI). - The study estimated cumulative incidence of HBsAg loss after antiretroviral therapy (ART) using Kaplan-Meier analysis; most clearances occurred within the first 3–4 years of therapy. - HBsAg clearance occurred in 7 of 12 HBsAg-positive patients (58%). The Kaplan-Meier cumulative incidence reached ~25% by 2 years and ~64.3% by ~4.4 years, with no further clearances observed during later follow-up. - Clearance was associated with preserved immune function (CD4 ≥200 cells/μL: 71% vs 0%) and better HIV control (HIV-RNA <10^5 copies/mL: 86% vs 20%). - HBV-DNA levels were significantly higher in the HBsAg clearance group than in OBI cases (adjusted p = 0.007), indicating that detectable HBV replication accompanied clearance events in this cohort. - All sequenced OBI cases were genotype C2. One OBI case also carried a rare substitution in the HBsAg 'a' determinant region, N131K, a change reported infrequently in genotype A sequences in HBV databases. - The authors suggest that a rare **'a' determinant substitution (N131K)** may produce false-negative HBsAg results and thus underlie OBI, a finding relevant when selecting **NRTI-sparing regimens** for people with HIV. - The study was approved by the Kumamoto University Ethics Committee (Approval No. 1942); authors report no competing interests. All data are contained within the manuscript.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=mqRs5PxCI.r_JlHtQQWmJwEe2yZPudZivckoeHG2ERU-1788566875.5090868-1.2.1.1-SZUI91IoTy.A0WtGJSIn8pleId.22ES8ln_HKvrRuNg1EVMRM4gqPsTYQzDTp98x) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.02.26362028v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Hepatitis B surface antigen clearance in HIV/HBV-coinfected patients: associated clinical factors and a rare amino acid substitution underlying occult infection Manabu Takabayashi, [ View ORCID Profile](http://orcid.org/0000-0001-7589-9514)Tomofumi Nakamura, [ View ORCID Profile](http://orcid.org/0000-0002-7333-2327)Hirotomo Nakata, [ View ORCID Profile](http://orcid.org/0000-0002-7939-2080)Jun-ichirou Yasunaga, [ View ORCID Profile](http://orcid.org/0000-0002-9649-8821)Shuzo Matsushita doi: https://doi.org/10.64898/2026.09.02.26362028 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Manabu Takabayashi 1 Kumamoto University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Manabu%2BTakabayashi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Takabayashi%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AManabu%2BTakabayashi%2B) Tomofumi Nakamura 1 Kumamoto University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tomofumi%2BNakamura%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nakamura%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATomofumi%2BNakamura%2B) * [ORCID record for Tomofumi Nakamura](http://orcid.org/0000-0001-7589-9514 "Open in new tab") * For correspondence: tomona@kumamoto-u.ac.jp Hirotomo Nakata 1 Kumamoto University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hirotomo%2BNakata%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nakata%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHirotomo%2BNakata%2B) * [ORCID record for Hirotomo Nakata](http://orcid.org/0000-0002-7333-2327 "Open in new tab") Jun-ichirou Yasunaga 1 Kumamoto University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jun-ichirou%2BYasunaga%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Yasunaga%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJun-ichirou%2BYasunaga%2B) * [ORCID record for Jun-ichirou Yasunaga](http://orcid.org/0000-0002-7939-2080 "Open in new tab") Shuzo Matsushita 2 Kumamoto University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Shuzo%2BMatsushita%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Matsushita%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AShuzo%2BMatsushita%2B) * [ORCID record for Shuzo Matsushita](http://orcid.org/0000-0002-9649-8821 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.02.26362028v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1292926/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.02.26362028v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1292926/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.02.26362028v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1292926/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.02.26362028v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1292926/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.02.26362028v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1292926/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: HBV coinfection is more common among people with HIV than in the general population. Nucleotide reverse transcriptase inhibitors (NRTIs) in antiretroviral therapy (ART) are also active against HBV. Growing use of NRTI-sparing regimens raises concern about HBV reactivation. Objectives: To determine the rate, cumulative incidence, and factors associated with HBsAg clearance in HIV/HBV-coinfected patients, and to characterize the genetic/structural basis of occult HBV infection (OBI) in the same cohort. Study design: We retrospectively reviewed 256 people with HIV at Kumamoto University Hospital in Japan (1986-2025), stratified by HBsAg clearance status; clinical factors were compared and cumulative incidence estimated by Kaplan-Meier analysis. OBI cases underwent HBsAg-region sequencing. Results: Fifteen patients were analyzed (12 HBsAg-positive, 3 OBI). HBsAg clearance occurred in 7/12 (58%). The Kaplan-Meier estimated cumulative incidence reached 25% by 2 years and 64.3% at approximately 4.4 years, after which no additional clearance events were observed during follow-up. Clearance was associated with higher CD4 (≥200 cells/μL: 71% vs 0%) and lower HIV-RNA ( The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.02.26362028v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.31.26361823v1 "Identification of the Minimal Clinically Important Difference \(MCID\) for Childhood Autism Rating Scale Second Edition \(CARS2\) in children with ASD")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.31.26361543v1 "Patterns and Outcomes of Occupational Injuries in Emergency Departments at Nigerian Hydropower Plant Hospitals: A Retrospective Study") Posted September 04, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.02.26362028v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/04/2026.09.02.26362028.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.02.26362028v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/04/2026.09.02.26362028.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Hepatitis B surface antigen clearance in HIV/HBV-coinfected patients: associated clinical factors and a rare amino acid substitution underlying occult infection Manabu Takabayashi, Tomofumi Nakamura, Hirotomo Nakata, Jun-ichirou Yasunaga, Shuzo Matsushita medRxiv 2026.09.02.26362028; doi: https://doi.org/10.64898/2026.09.02.26362028 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.02.26362028v1%26text%3DHepatitis%2520B%2520surface%2520antigen%2520clearance%2520in%2520HIV%2FHBV-coinfected%2520patients%253A%2520associated%2520clinical%2520factors%2520and%2520a%2520rare%2520amino%2520acid%2520substitution%2520underlying%2520occult%2520infection "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.02.26362028v1%26t%3DHepatitis%2520B%2520surface%2520antigen%2520clearance%2520in%2520HIV%2FHBV-coinfected%2520patients%253A%2520associated%2520clinical%2520factors%2520and%2520a%2520rare%2520amino%2520acid%2520substitution%2520underlying%2520occult%2520infection "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.02.26362028v1%26title%3DHepatitis%2520B%2520surface%2520antigen%2520clearance%2520in%2520HIV%2FHBV-coinfected%2520patients%253A%2520associated%2520clinical%2520factors%2520and%2520a%2520rare%2520amino%2520acid%2520substitution%2520underlying%2520occult%2520infection%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.02.26362028v1%26title%3DHepatitis%2520B%2520surface%2520antigen%2520clearance%2520in%2520HIV%2FHBV-coinfected%2520patients%253A%2520associated%2520clinical%2520factors%2520and%2520a%2520rare%2520amino%2520acid%2520substitution%2520underlying%2520occult%2520infection "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.02.26362028) ## Subject Area * [HIV/AIDS ](https://www.medrxiv.org/collection/hiv-aids) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (615) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (896) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (327) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4776) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (476) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (410) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (645) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1617) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15853) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1196) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6996) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (727) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1059) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4998) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1428) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1741) * [Hematology](https://www.medrxiv.org/collection/hematology) (583) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1338) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16251) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1162) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (665) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (151) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (721) * [Neurology](https://www.medrxiv.org/collection/neurology) (7207) * [Nursing](https://www.medrxiv.org/collection/nursing) (365) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1074) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1233) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1002) * [Oncology](https://www.medrxiv.org/collection/oncology) (3581) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1039) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (393) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (448) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (466) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (704) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1781) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (733) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (759) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5844) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9705) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2392) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1436) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1245) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (635) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (769) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (577) * [Surgery](https://www.medrxiv.org/collection/surgery) (769) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (107) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (303) * [Urology](https://www.medrxiv.org/collection/urology) (286) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/commenting_on_preprints) for more information. Share this comments tab (click to copy link)Copied! TRiP medRxiv partners with journals and review services to enable posting of peer reviews and editorial decisions related to preprints they are evaluating. Reviews are posted with the consent of the authors. TRiP reviews are part of a peer review pilot project in which participating organizations post peer reviews of manuscripts they are evaluating _There is no TRiP material for this paper._ Community Reviews medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the prep
## Related Clinical Research

- [Social Vulnerability and Risk of Mortality, Liver Disease, and Organ Complications in US Adults Wi](https://medichelpline.com/clinical-feed/medrxiv-19-multidimensional-social-vulnerability-and-hepatic-and-extrahepatic-outcomes-in.md)
- [Social Determinants of Health Are More Common in HIV/HBV Coinfection Than in HIV or HBV Alone](https://medichelpline.com/clinical-feed/medrxiv-17-social-determinants-of-health-in-hiv-hbv-coinfection-compared-with-hiv-and-hbv.md)
- [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md)
- [MMR vaccines: separating measles, mumps, rubella shots — myths and facts](https://medichelpline.com/clinical-feed/medical-news-today-0-should-the-measles-mumps-rubella-vaccines-be-separate-myths-vs-facts.md)
- [Strategies to improve access to pediatric HIV services in Malawi: study protocol](https://medichelpline.com/clinical-feed/pubmed-42691038.md) (DOI: 10.1371/journal.pone.0357408)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.